Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 823

1.

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ.

Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11.

PMID:
19671877
[PubMed - indexed for MEDLINE]
Free Article
2.

Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.

Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, Assi H, Berman D, Siegel J, Weber JS.

J Immunother. 2012 Jan;35(1):73-7. doi: 10.1097/CJI.0b013e31823735d6.

PMID:
22130164
[PubMed - indexed for MEDLINE]
3.

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL.

Cancer Immun. 2010 Nov 24;10:11.

PMID:
21090563
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS.

Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16.

PMID:
20082117
[PubMed - indexed for MEDLINE]
5.

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M.

J Clin Oncol. 2012 Jun 10;30(17):2046-54. doi: 10.1200/JCO.2011.38.4032. Epub 2012 Apr 30. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.

PMID:
22547592
[PubMed - indexed for MEDLINE]
Free Article
6.

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13.

PMID:
19139884
[PubMed - indexed for MEDLINE]
7.

Phase I/II study of ipilimumab for patients with metastatic melanoma.

Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E.

J Clin Oncol. 2008 Dec 20;26(36):5950-6. doi: 10.1200/JCO.2008.16.1927. Epub 2008 Nov 17.

PMID:
19018089
[PubMed - indexed for MEDLINE]
Free Article
8.

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.

J Clin Oncol. 2008 May 1;26(13):2178-85. doi: 10.1200/JCO.2007.14.8288.

PMID:
18445842
[PubMed - indexed for MEDLINE]
Free Article
9.

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U.

J Clin Oncol. 2009 Jun 10;27(17):2823-30. doi: 10.1200/JCO.2007.15.7636. Epub 2009 Apr 6.

PMID:
19349552
[PubMed - indexed for MEDLINE]
Free Article
10.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D.

J Transl Med. 2011 Nov 28;9:204. doi: 10.1186/1479-5876-9-204.

PMID:
22123319
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.

Miehlke S, Madisch A, Bethke B, Morgner A, Kuhlisch E, Henker C, Vogel G, Andersen M, Meier E, Baretton G, Stolte M.

Gastroenterology. 2008 Nov;135(5):1510-6. doi: 10.1053/j.gastro.2008.07.081. Epub 2008 Aug 7.

PMID:
18926826
[PubMed - indexed for MEDLINE]
12.

Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial.

Miehlke S, Heymer P, Bethke B, Bästlein E, Meier E, Bartram HP, Wilhelms G, Lehn N, Dorta G, DeLarive J, Tromm A, Bayerdörffer E, Stolte M.

Gastroenterology. 2002 Oct;123(4):978-84.

PMID:
12360457
[PubMed - indexed for MEDLINE]
13.

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M.

Lancet Oncol. 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8. Epub 2012 Aug 13.

PMID:
22894884
[PubMed - indexed for MEDLINE]
14.

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD.

N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.

PMID:
21639810
[PubMed - indexed for MEDLINE]
Free Article
15.

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M.

Cancer Immunol Immunother. 2012 Jan;61(1):41-8. doi: 10.1007/s00262-011-1089-0. Epub 2011 Aug 11.

PMID:
21833591
[PubMed - indexed for MEDLINE]
16.

Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group.

Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O.

Chest. 1999 Aug;116(2):424-31.

PMID:
10453872
[PubMed - indexed for MEDLINE]
17.

Ipilimumab for advanced melanoma: a nursing perspective.

Ledezma B.

Oncol Nurs Forum. 2009 Jan;36(1):97-104. doi: 10.1188/09.ONF.97-104. Review.

PMID:
19136343
[PubMed - indexed for MEDLINE]
18.

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.

Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ.

Melanoma Res. 2011 Dec;21(6):530-4. doi: 10.1097/CMR.0b013e32834d3d88.

PMID:
22051508
[PubMed - indexed for MEDLINE]
19.

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

Weber J.

Oncologist. 2007 Jul;12(7):864-72. Review.

PMID:
17673617
[PubMed - indexed for MEDLINE]
Free Article
20.

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L.

J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9.

PMID:
9660028
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk